MedDataX Logo

Special Drug Use Investigation for PAXIL (Paroxetine) Social Anxiety Disorder (Long-term)

NCT ID: NCT01376271

Last Updated: 2014-07-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-01-31

Study Completion Date

2013-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is designed to evaluate the safety and efficacy of paroxetine on the long-term use in Japanese Social Anxiety Disorder (SAD) subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long-term Study Of Paroxetine in Women and Men

NCT00264654

Social Phobia
COMPLETED PHASE3

Social Anxiety Disorder Study Of Paroxetine

NCT00318669

Social Phobia
COMPLETED PHASE3

Special Drug Use Investigation for PAXIL Tablet (Investigation in Case of Administered From 20mg/Day)

NCT01371474

Panic Disorder
COMPLETED

Special Drug Use Investigation for PAXIL Tablet (Pediatric Panic Disorder)

NCT01376128

Panic Disorder
COMPLETED

A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder

NCT02432703

Phobic Disorders
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Social Phobia

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects prescribed paroxetine tablets

Subjects with SAD prescribed paroxetine tablets during study period

Paroxetine

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Paroxetine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects who are diagnosed as having SAD
* Subjects who are expected to use paroxetine tablets for the first time

Exclusion Criteria

* Subjects taking pimozide
* Subjects taking monoamine oxidase (MAO) inhibitor or within two weeks after discontinuation of MAO inhibitor
* Subjects with hypersensitivity to paroxetine
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

114102

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder
NCT00677352 COMPLETED PHASE4
Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder
NCT00074802 COMPLETED PHASE3
A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder
NCT00470483 COMPLETED PHASE1
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
NCT00658372 TERMINATED PHASE3
Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD)
NCT00557622 TERMINATED PHASE2
Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome
NCT00114127 COMPLETED PHASE3
Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD)
NCT00560612 COMPLETED PHASE4
A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder
NCT00273039 COMPLETED PHASE2
BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder
NCT00839397 COMPLETED PHASE3
A Combination Therapy In Patients With Social Anxiety Disorder
NCT00403962 COMPLETED PHASE2
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
NCT00658762 TERMINATED PHASE3
A Study of NTX-1472 in Social Anxiety Disorder
NCT07323784 RECRUITING PHASE2
Treatment Of Patients With Social Anxiety Disorder
NCT00397722 COMPLETED PHASE2
PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients
NCT00343707 COMPLETED PHASE2
Study Of Generalized Anxiety Disorder
NCT00135525 COMPLETED PHASE2
A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
NCT00735267 TERMINATED PHASE3
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder
NCT00266747 COMPLETED PHASE3
Long Term Treatment of Panic Disorder With Clonazepam or Paroxetine
NCT02852577 COMPLETED PHASE4
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder
NCT00332891 COMPLETED PHASE3
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
NCT00658008 TERMINATED PHASE3
A Long-term Observational Study on the Efficacy of SSRIs or Combined Treatment(SSRIs+ CBT) in Panic Disorder Patients
NCT01674673 UNKNOWN
Trial of Paroxetine-CR for the Treatment of Patients With Post Traumatic Stress Disorder Remaining Symptomatic After Initial Exposure Therapy
NCT00121888 COMPLETED PHASE1/PHASE2
A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder
NCT00555139 COMPLETED PHASE1
Treatment of Panic Disorder: Long Term Strategies
NCT00000368 COMPLETED PHASE3
Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder
NCT00191022 COMPLETED PHASE2